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CTCs as Liquid Biopsy: Where Are 
We Now?
Laure Cayrefourcq and Catherine Alix-Panabières
Abstract
A few years ago, the analysis of circulating tumor cells (CTCs) in the blood 
of patients with cancer was defined by the term “real-time liquid biopsy.” Blood 
samples can be obtained and analyzed at the time of diagnosis and repeatedly 
during the systemic treatment. The analysis of the liquid biopsy has provided new 
insights into the biology of metastasis with important implications for the clinical 
management of cancer patients. In this review, we updated all technical strategies 
developed to improve enrichment, detection, and characterization of CTCs. We also 
focused on their biological properties as well as on their clinical relevance in differ-
ent cancer types. At the end, we opened the discussion to all the other circulating 
biomarkers used as liquid biopsy.
Keywords: circulating tumor cells, liquid biopsy, clinical relevance, circulating 
biomarkers, precision medicine
1. Introduction
A few years ago, the analysis of circulating tumor cells (CTCs) in the blood of 
patients with cancer was defined by the term “liquid biopsy” [1]. Blood samples 
can be obtained and analyzed at the time of diagnosis and during the systemic 
treatment. Detection of CTCs in circulation gives important information on the 
molecular properties of tumor lesions. This information contributes to the early 
detection of metastatic lesions and participates in the personalized treatment of 
cancer patients such as prognostic evaluation, stratification of patients for targeted 
therapies, real-time monitoring of treatment efficacy, identification of therapeutic 
target, and resistance mechanism.
The analysis of the liquid biopsy has provided new insights into the biology 
of metastasis with important implications for the clinical management of cancer 
patients (Figure 1). Numerous clinical studies and meta-analyses including large 
cohorts of patients have shown that the number of CTCs is an important indica-
tor of the risk of progression or death in patients with metastatic solid cancer 
(e.g., breast, prostate, colon, etc.) [2–6].
Despite the remarkable advances made in recent years, so far, liquid biopsy 
analyses are rarely implemented in routine patient testing. In-depth investigation of 
CTCs remains technically challenging. CTCs occur at the very low concentrations 
of one tumor cell in the background of millions of blood cells. Their identification 
and characterization require extremely sensitive and specific analytic methods. 
Moreover, up to now, results obtained with liquid biopsy analysis did not lead yet to 
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validated guidelines for treatment and patient management. Nevertheless, technical 
advances and encouraging clinical studies demonstrated that liquid biopsy holds 
great promise for revolutionizing cancer diagnostics in a soon future.
Here, we will outline the advantages and challenges of CTCs as liquid biopsy in 
oncology by discussing the strategies for enrichment, detection, and characteriza-
tion linked to the biology of these cells. Moreover, the potential of CTC analysis for 
clinical utility will be argued as well as other circulating biomarkers.
2.  Technical strategies for enrichment, detection, and characterization 
of CTCs
At the moment, in-depth investigation of CTCs still remains technically chal-
lenging as they are every rare events in blood circulation. Their identification and 
characterization require extremely sensitive and specific analytic methods, which 
are usually a combination of enrichment and detection procedures (Figure 2). 
The different strategies to analyze CTCs are described in this chapter, and all the 
advantages/disadvantages plus the commercial status are summarized in Table 1.
2.1 Strategies for CTC enrichment
Up to date, a large panel of technologies was designed to enrich CTCs from the 
surrounding normal hematopoietic cells. These enrichment methods rely on differ-
ent properties of CTCs: (a) biological properties (e.g., surface protein expression) 
and (b) physical properties (e.g., size, density, electric charges, and deformability).
Biological properties are mainly used in immunological procedures with anti-
bodies against either tumor-associated antigens (positive selection) or common 
leukocytes antigen CD45 (negative selection). Positive enrichment typically attains 
high cell purity, which depends on antibody specificity. Among the current positive 
systems, most of the technologies targeted the epithelial cell adhesion molecule 
(EpCAM) antigen, as the FDA-cleared CELLSEARCH® system which is frequently 
compared for all new CTC detection methods as the gold standard. However, 
Figure 1. 
From the blood sample toward the precision medicine in cancer patients.
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capturing CTCs lacking EpCAM expression has involved the use of cocktails of 
antibodies against various other epithelial cell surface antigens (e.g., EGFR, MUC1) 
or against tissue-specific antigen (e.g., PSA, HER2) and against mesenchymal or 
stem-cell antigens (e.g., Snail, ALDH1) [7]. Positive selection of CTCs requires 
an assumption about the unknown nature of CTCs in an individual blood sample. 
This bias is avoided by negative selection in which the blood sample is depleted 
of unwanted cells. Indeed, negative enrichment targets and removes background 
cells, such as leukocytes, using antibodies against CD45 (which is not expressed on 
carcinomas or other solid tumors) and other leukocyte antigens, to achieve a CTC-
enriched sample. Moreover, negative enrichment technologies evade some of the 
pitfalls of positive enrichment; for example, CTCs are not tagged with a difficult-
to-remove antibody, they are not activated or modified via an antibody-protein 
Figure 2. 
Strategies for enrichment, detection, and characterization of CTCs.
Molecular Medicine
4
interaction, and antibody selection does not bias the subpopulation of CTCs 
captured. However, these advantages come at the cost of purity, as negative enrich-
ment strategies typically have a much lower purity than positive enrichment [8–10] 
and require a suitable CTC detection step.
Table 1. 
Advantages, disadvantages, and commercial status of technologies for enrichment, detection, and 
characterization of CTCs.
5CTCs as Liquid Biopsy: Where Are We Now?
DOI: http://dx.doi.org/10.5772/intechopen.84366
These last years, numerous marker-independent techniques have been devel-
oped for CTC isolation and detection. Label-free enrichment process based on 
physical properties, such as density, size, deformability, and electric charge, have 
come to avoid molecular bias induced by variability of cell biomarker expression 
associated with tumor heterogeneity. Mostly used, size and density technologies 
like microfiltration technologies, based on the precedent that CTCs generally 
exhibit a larger morphology than leukocytes, or microfluidic devices using inertial 
focusing to separate CTCs from blood are developed by several companies such 
as ScreenCell® [11], ISET® [12], CellSieve™ [13, 14], Parsortix™ [15], or Vortex 
[16]. Such technologies or approaches have the advantages of being less compli-
cated, sometimes rapid, and require minimal equipment. However, some of these 
approaches may be prone to clogging, and the release of the CTCs into suspension 
for further analysis is challenging.
2.2 Strategies for CTC detection
After enrichment, the CTC fraction still contains a substantial number of leuko-
cytes, and CTCs need to be specifically identified at the single-cell level by a robust 
and reproducible method that can distinguish them from normal blood cells.
Immunological technologies are the most frequent methods used for CTC detec-
tion using a combination of membrane and/or intracytoplasmic anti-epithelial, 
anti-mesenchymal, and anti-tissue-specific marker or antitumor-associated 
antibodies [7]. However, many CTC assays use the same identification step as the 
CELLSEARCH® system: cells are fluorescently stained for cytokeratins (CK), the 
common leukocyte antigen CD45, and a nuclear dye (DAPI).
Nucleic acid-based CTC detection methods are the most widely used alternatives 
to immunological assays to identify CTCs. These techniques identify specific tumor 
DNA or mRNA to confirm the presence of CTCs indirectly [17]. Detection involves 
designing specific primers supposedly associated with CTC-specific genes. These 
genes either code for tissue-, organ-, or tumor-specific proteins or, more specifi-
cally, contain known mutations, translocations, or methylation patterns found in 
cancer cells [18]. These methods have the highest sensitivity but lack specificity, 
owing to the potential of captured noncancerous cells to generate false-positive 
signals, thus decreasing the overall accuracy. Considering the genetic heterogeneity 
of CTCs, multiplex PCR, such as the AdnaTest kit (AdnaGen AG), could overcome 
this limitation [19, 20].
Furthermore, functional assays that exploit aspects of live cellular activity for 
CTC detection have the particularity to focus on the discovery of the “metastasis-
competent cells.” The functional epithelial immunospot (EPISPOT) assay was 
introduced for in vitro CTC detection and focuses only in viable CTCs [21]. This 
technology assesses the presence of CTCs based on secretion, shedding, or release 
of specific proteins during 24–48 h of short-term culture [22]. More recently, Tang 
et al. described a high-throughput metabolic-based assay for rapid detection of rare 
metabolically active tumor cells in pleural effusion and peripheral blood of lung 
cancer patients [23]. In vivo, important information can be obtained by transplan-
tation of patient-derived CTCs into immunodeficient mice: tumors that could grow 
after xenotransplantation of enriched CTCs have the characteristics of metastasis-
initiator cells [8].
2.3 Strategies for CTC characterization
CTCs hold the key to understand the biology of metastasis and provide a bio-
marker to noninvasively measure the evolution of tumor subclone during treatment 
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and disease progression. Improvements in technologies to yield purer CTC popula-
tions make better cellular and molecular investigation. Characterization of CTCs 
allows better insight into tumor heterogeneity, within most assays, including 
immunofluorescence, array CGH, next-generation sequencing (NGS) of both DNA 
and RNA, and fluorescence in situ hybridization.
Protein analyses on single CTCs are currently performed by immunostaining 
with antibodies directed against protein of interest. Multiple labeling is possible 
but usually restricted to a few proteins of interest for tumor cell biology and cancer 
therapy. This may help to identify signaling pathways relevant to metastasis devel-
opment and treatment responses. In breast cancer patient, the HER2 status of CTCs 
could be assessed and shows discrepancies with primary tumor status [24, 25]. 
More recently, immune checkpoint regulators such as programmed death-ligand 1 
(PD-L1) have become exciting new therapeutic targets and could be used for liquid 
biopsy in future clinical trials on patients undergoing immune checkpoint blockage 
[26, 27].
Immunological detection and characterization offer the advantage of allowing 
isolation of stained CTCs for subsequent molecular characterization. While manual 
isolation by micromanipulation of CTCs is possible [28], it is rather arduous and 
time-consuming. An alternative automated single-cell selection device has been 
therefore developed. The DEPArray™ technology based on a dielectrophoresis 
strategy by trapping single cells in DEP cages [29] is designed for single-cell recov-
ery of CTCs. Multiple clinical studies have used DEPArray™ to detect and recover 
single CTCs for subsequent genetic analyses [30–32].
Among single-cell sequencing to identify genomic and transcriptomic 
characteristics of CTCs, most studies have focused on genomic analyses and 
carried out whole genome amplifications (WGAs) to increase the amount of 
DNA, which is subsequently subjected to the analyses of specific mutations and 
copies number variations using conventional and next-generation sequencing 
technologies [28, 33, 34]. As an example, CTCs with mutated KRAS genes will 
escape anti-EGFR therapy, and their early detection might help to guide therapy 
in individual patients. Besides isolation of single CTCs, a 3–4 log units enrich-
ment step are enough to detect CTCs based on recently developed highly sensi-
tive technologies (e.g., droplet digital PCR) [35].
Another approach is fluorescence in situ hybridization (FISH) analysis of 
single CTCs identified by immunocytochemistry [36, 37]. Such an immuno-FISH 
approach can be combined with automated detection of CTCs and might be easier 
to implement in future clinical diagnostics. Recently, padlock probe technology, 
which enables in situ analysis of AR-V7 in CTCs, showed that 71% (22 of 31) of 
CRPC patients had detectable AR-V7 expression ranging from low to high expres-
sion [38]. Patients with AR-V7-positive circulating tumor cells (CTCs) have greater 
benefit of taxane-based chemotherapy than novel hormonal therapies, indicating a 
treatment-selection biomarker [39, 40].
Finally, these last years, many teams tried to obtain CTC lines by culturing CTCs 
ex vivo. The establishment of in vitro cultures and permanent lines from CTCs has 
become a challenging task. Indeed, CTC lines could be used to identify proteins 
and pathways involved in cancer cell stemness and dissemination and also to test 
new drugs to inhibit metastasis-competent CTCs. Ex vivo CTC cultures have been 
established for breast [41, 42], prostate [43], lung [44], colon [22], and head and 
neck cancer [45]. To our knowledge, permanent CTC lines have been described only 
from circulating colon cancer cells: one before (CTC-MCC-41) [22, 46] and eight 
after the initiation of the anticancer treatment [47].
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3. Biology of CTCs
3.1 Epithelial to mesenchymal plasticity
Epithelial to mesenchymal transition (EMT), which is characterized by the 
downregulation of epithelial proteins and upregulation of mesenchymal proteins, 
is a complex process that supports the migratory capacity of epithelial tumor cells 
and is thought to play a crucial role in promoting cancer metastasis. EMT led to 
increased motility via rearrangements of cellular contact junctions and loss of cell 
adhesion (i.e., E-cadherin, N-cadherin, claudins), plus epithelial cell morphology 
through cytoskeleton modification (i.e., cytokeratin, vimentin, fibronectin, etc.) 
[48]. This invasive phenotype enables cancer cells to pass through the basal mem-
brane and endothelial barriers of blood vessels to reach bloodstream. However, it is 
still unclear what degree of EMT is needed in tumor cells to attain the circulation.
Despite the wealth of experimental data, the exact role of EMT in cancer 
patients remains more controversial. Over the past 10 years, the development of 
sensitive technologies that allow the detection and molecular characterization of 
CTCs helped to shed new light into the importance of EMT for human tumor cell 
dissemination [7, 49]. All these data lead now to a new trend, focused on plasticity 
of tumor cell: epithelial to mesenchymal plasticity (EMP) associated with stemness. 
This process is today considered as a central actor of the metastatic cascade, provid-
ing tumor cells the ability to adapt to the different microenvironments encountered 
during metastatic spread to colonized organs (i.e., adjacent stroma, blood, newly 
colonized organs).
CTCs with mesenchymal and stemness features can be attributed in some 
clinical studies to higher disease stages and metastasis [50–52] and even to therapy 
response and worse outcome [53–55]. However, the published studies addressing 
the impact of mesenchymal-like CTCs show heterogeneity with regard to assay 
specificity, size of cancer and control groups, and endpoint parameters.
To conclude, evaluation of the EMT and stem-cell markers in CTCs may provide 
information of clinical interest, and using these markers to classify CTCs can eluci-
date CTC heterogeneity. Nevertheless, studies still suffer from lack of standardized 
procedures and small sample sizes. Therefore, larger well-designed clinical trials are 
needed to further illuminate the potential values of EMT markers in CTCs.
3.2 Anoikis resistance
In normal tissue, adhesion to appropriate extracellular matrix proteins is 
essential for survival. Loss of this adhesion induces cell death which has been 
termed “anoikis.” Anoikis is a physiologically relevant process for tissue homeostasis 
and development because it prevents detached epithelial cells from colonizing 
elsewhere, thereby inhibiting dysplastic cell growth or attachment to an inappropri-
ate matrix [56]. Dysregulation of anoikis, such as anoikis resistance, is a critical 
mechanism in tumor metastasis. If cells acquire oncogenic signals that are able to 
overcome this machinery, they gain the ability to survive outside their normal envi-
ronment in the absence of adhesion to the extracellular matrix. The tumor cells that 
acquire anoikis resistance can survive detachment from their primary site, traveling 
through the circulatory and lymphatic systems to disseminate to ectopic locations 
[57]. Different studies have shown that the death receptor pathway of caspase 
activation mediates anoikis; thus, defects in this pathway such as overexpression of 
the caspase-8 inhibitor FLIP can turn cell resistant to anoikis. Similarly, resistance 
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to anoikis can be conferred by roadblocks in the mitochondrial pathway, such as 
overexpression of the Bcl-2 family of anti-apoptotic proteins [57].
The investigation of molecular mechanisms involved in cancer cell survival 
while they are leaving the adherent microenvironment of the tumor to the circula-
tory system is important to understand the process by which cancer can spread to 
distant organs, as well as to design new therapeutics to inhibit the spread of the 
disease.
3.3 Escape to the immune system
Once in the bloodstream, CTCs face several natural obstacles that hinder the 
metastatic process. One of the main obstacles that CTCs face in the blood is the 
attack of the immune system. Lots of work was done to understand mechanisms 
involve in the battle between the immune system’s capabilities to fight cancer and 
the immune-suppressive processes that promote tumor growth. Several biomark-
ers showed up from this work; for example, in colorectal cancer, immune escape 
was observed by the upregulation of CD47, a “don’t eat me signal” that prevents 
CTCs from macrophage and dendritic cell attack [58]. The most clinically advanced 
biomarkers are the programmed death-1 (PD-1) and its ligand (PD-L1). PD-L1 
expressed in tumors has been highlighted to function as a key component of the 
cancer-immunity cycle by preventing the immune system from destroying cancer 
cells. PD-1 receptor is a surface protein expressed on activated T-cells, and its ligand 
PD-L1 is expressed on the surface of antigen-presenting cells. The formation of the 
PD-1/PD-L1 complex induces a strong inhibitory signal in the T-cell, which leads 
to a reduction of cytokine production and a suppression of T-cell proliferation [59]: 
the immune system is misled by the cancer cells expressing PD-L1 and does not 
destroy them. That understanding led to the development of immune checkpoint 
inhibitor therapies, antibodies against both PD-1 and PD-L1, and remarkable clini-
cal responses which have been seen in several different malignancies including, but 
not limited to, melanoma, lung, kidney, and bladder cancers [59].
However, CTCs can use several mechanisms to survive in the circulatory system. 
For example, these cells can couple to reactive platelets. Several hypotheses propose 
that the surface coating of platelets may serve as a shield against immune assault 
or that platelets may load the major histocompatibility complex to CTCs to imitate 
host cells and therefore avoid immune surveillance [60]. The aggregation of CTCs 
with platelets, stromal fibroblasts, and leukocytes leads to the formation of floating 
complexes and increases the survival of CTCs in the bloodstream by avoiding anoi-
kis and killing by immune cells [61]. In addition, the vascular endothelial growth 
factor (VEGF), secreted by platelets, is able to affect the maturation of dendritic 
cells that play a key role in antigen presentation [62].
3.4 CTC microemboli
An alternative mechanism for metastasis has emerged from recent studies, the 
collective migration of tumor cells by clusters of CTCs. CTC clusters are defined 
as groups of tumor cells (more than two or three cells, varied among studies) that 
travel together in the bloodstream. Thus, in the blood circulation, CTCs can be 
found both as single tumor cells and clusters of tumor cells in patients with an 
advanced stage of the cancer. Study using mouse models with tagged mammary 
tumors demonstrates that these clusters arise from oligoclonal tumor cell groupings 
and not from intravascular aggregation events [63]. Moreover, CTC clusters have 
23- to 50-fold increased metastatic potential. Even fewer in number, clusters of 
CTCs possess much higher metastatic potential than individual CTCs.
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Patients with CTC microemboli or clusters in their bloodstream have signifi-
cantly worse overall and progression-free survival than those with only individually 
migrating single CTCs [63]. The prognostic value of CTC clusters can be estimated 
by clinical observations.
Current studies have partially elucidated the reasons for CTC clusters to have 
higher potential of metastasis. First, tumor cells within CTC clusters showed 
prolonged survival and decreased apoptosis [64]. Second, the physical specialty 
of CTC clusters allows for a greater likelihood of it residing in distant organs. 
Microvasculature of viscera can retain large CTCs; thus, it can retain CTC clusters 
more easily [65].
4. Clinical relevance of CTCs
Despite many clinical validation studies, CTCs have not been included yet into 
the clinical guidelines (e.g., ASCO guidelines at http://www.asco.org/practice-
guidelines/quality-guidelines/guidelines). Although CTC enumeration can improve 
current tumor staging and contribute to the early assessment of therapy effects, the 
clinical utility of CTCs remains to be addressed in interventional studies (i.e., its 
capacity to decide adopting or to rejecting a therapeutic action).
In this chapter, we highlighted the clinical relevance of CTCs in breast, prostate, 
colon, and lung cancer. Figure 3 illustrates how CTCs as liquid biopsy can guide 
clinicians to personalized medicine.
4.1 Breast
More advanced studies, regarding clinical utility of CTCs, are related to meta-
static breast cancer (MBC). Sequential CTC enumeration has been shown in a large 
multicenter prognostic study to be superior to conventional serum protein markers 
(CA-15-3, CEA) for early detection of therapy failure in MBC [5]. However, in the 
Figure 3. 
CTC as liquid biopsy for precision medicine.
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interventional trial SWOG 0500 (NCT00382018), although the prognostic sig-
nificance of CTCs was confirmed, the CTC-driven switch to an alternate cytotoxic 
therapy was not effective in prolonging overall survival for MBC patients with 
persistently increased CTCs after 21 days of therapy [66]. The inconvenient of 
these kinds of interventional biomarker-driven studies is the fact that the result is 
dependent of the therapy efficacy. This strategy can only work if there is an effi-
cient therapy for the cohort identified by the test.
Another promising approach is the stratification of patients to chemotherapy 
or hormonal therapy based on CTC enumeration like in the interventional STIC 
CTC METABREAST clinical trial (NCT0 1,710,605) for MBC patients [67]. Besides 
CTC enumeration, stratification based on CTC phenotype might become also an 
important strategy. Stratification of MBC patients based on HER2 status of CTCs is 
currently tested in the DETECT III trial [67].
Other possible uses for CTC detection include prognostication in early stage 
patients, identifying patients requiring adjuvant therapy. The SUCCESS study 
provides strong evidence of the prognostic relevance of CTCs in early breast cancer 
before and after adjuvant chemotherapy in a large patient cohort [68]. This study 
outlines the potential of the CTC analysis at primary diagnostic to evaluate indi-
vidual risk and points that they may use for treatment management in early stage 
of cancer. These data have been confirmed by Bidard et al. who conducted a meta-
analysis in nonmetastatic breast cancer patients treated by neoadjuvant chemother-
apy (NCT) to assess the clinical validity of CTC detection as a prognostic marker 
[69]. They showed that CTC count is an independent and quantitative prognostic 
factor in early breast cancer patients treated by NCT. Liquid biopsy complements 
current prognostic models based on tumor characteristics and response to therapy. 
Moreover, Trapp et al. demonstrated recently that the presence of CTCs 2 years 
after chemotherapy was associated with decreased OS and DFS. Based on these 
results, active individualized surveillance strategies for breast cancer survivors 
based on biomarkers should be reconsidered [70].
4.2 Prostate
For men with metastatic castration-resistant prostate cancer (mCRPC), the 
CELLSEARCH® system method for CTCs enumeration is the only FDA-cleared 
CTC test available clinically. The CTC count has been shown to provide prognostic 
value and was associated with treatment response in mCRPC patients, in several 
recent studies [4, 71–73], indicating a clear value as a patient-level indicator of 
survival. However, despite increasing evidence that CTCs could be used to monitor 
disease progression in mCRPC [18], CTC use is still limited to clinical trials in aca-
demic centers. Clinical utility of CTCs, reflecting the ability of this test to favorably 
change outcomes, is still an unmet clinical need in prostate cancer [74]. The first 
interventional clinical trial in prostate cancer that will show the clinical utility of 
CTCs should start in 2019 (TACTIK project—NCT03101046).
Moreover new data suggest that CTCs may harbor genetic information (such as 
the androgen receptor splice variant 7, AR-V7) relevant to changing clinical man-
agement and predicting treatment sensitivity or resistance to cancer therapies such 
as enzalutamide, abiraterone, and taxane-based chemotherapies [39].
Regarding nonmetastatic cancer patient, a recent European TRANSCAN study 
CTC-SCAN investigated the feasibility of detecting CTCs in nonmetastatic high-
risk prostate cancer (PCa) patients by combining the CELLSEARCH® platform, 
the in vivo CellCollector® capture system, and the EPISPOT assay. The observed 
correlation, with established risk factors and the persistence of CTCs 3 months 
after surgery, suggested a potential clinical relevance of CTCs as markers of 
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minimal residual disease (MRD) in PCa [75]. CTC-based liquid biopsies have the 
potential to monitor MRD in patients with nonmetastatic prostate cancer although 
follow-up evaluations are now required to assess how to provide independent 
prognostic information. A new European project (Transcan—PROLIPSY) will 
assess whether CTCs in combination with exosomes and ctDNA as noninvasive 
liquid biopsy allow the diagnosis of prostate cancer and the evaluation of its 
aggressiveness.
4.3 Colon
In 2008, Cohen et al. demonstrated the independent prognostic and predictive 
value of CTCs for patients initiating chemotherapy for metastatic colorectal cancer 
(mCRC) [2]. Since this first publication defining a cutoff of three CTCs, different 
meta-analyses have confirmed that baseline levels of CTC count is an important 
prognostic factor for PFS and OS in patients with mCRC [76–78].
Despite the strong evidence of a prognostic significance of CTC count, there is no 
solid evidence demonstrating the interest of CTC count for therapeutic strategy, and 
this biomarker is rarely used in the management of patients with mCRC. However, 
patients with high CTC counts recruited in a phase II study could benefit from a 
more intense chemotherapeutic regimen [79]. These preliminary data require valida-
tion in randomized trials. Moreover, Lalmahomed et al. failed to show a prognostic 
effect of CTCs for early relapse after the resection of colorectal liver metastases [80].
4.4 Lung
The role of CTCs in non-small cell lung cancer (NSCLC) has been addressed 
in several clinical trials. More specifically, the prediction of the outcome of 
patients with early and advanced NSCLC based on the CTC enumeration has been 
explored. The CTC count with the CELLSEARCH® system in advanced NSCLC 
patients who received standard chemotherapy was associated with a shorter PFS 
and OS, but standardize cutoff could not be observed [81–84]. Furthermore, 
analysis of CTCs from patients with metastatic NSCLC identified the expected 
EGFR-activating mutation in CTCs from 11 of 12 patients (92%) and in matched 
free plasma DNA from 4 of 12 patients (33%) [85]. The T790 M mutation, which 
confers drug resistance, was revealed in CTCs from patients who had received 
tyrosine kinase inhibitors, suggesting the strong potential gain of noninvasive 
liquid biopsy. Moreover, serial increases in CTC counts were associated with 
tumor progression, with the emergence of additional EGFR mutations in some 
cases. Recently, KRAS and EGFR mutations, relevant for treatment decisions, 
could be detected in CTCs and in the corresponding primary tumors of the same 
patients [86].
5. Other circulating biomarkers as liquid biopsy
Even if the term “liquid biopsy” was originally used for CTC analysis, currently, 
it includes all different circulating biomarkers like circulating cell-free DNA 
(cfDNA), microRNA (miRNA), and exosomes that are shed into the bloodstream 
by tumors and/or metastatic deposits, as well as tumor-educated platelets which are 
described to have a role in tumor metastasis. Like CTCs, all these other circulating 
biomarkers need to be validated in clinical trials. Table 2 summarizes observational 
and interventional clinical trials on breast, lung, prostate, and colorectal cancer 
registered in clinical.gov (A) and the applications (B).
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5.1 Circulating tumor DNA
Apoptotic and necrotic tumor cells are known to discharge cell-free nucleic 
acid fragments into the bloodstream of cancer patients. Although most circulating 
DNA is believed to originate from nonmalignant cells, an increased level of cfDNA 
was observed in blood of patients with late stage cancer [87]. Among the pool of 
total cfDNA, there is circulating tumor DNA (ctDNA) which cannot be specifi-
cally isolated from the total pool but can be detected by tumor-specific mutations 
[88]. In general, cfDNA can be analyzed from plasma by targeted or untargeted 
approaches. The targeted approaches involve the detection of known genetic 
changes, e.g., “druggable” mutations, with impact on therapy decisions [89]. The 
interest of cfDNA was demonstrated by Douillard et al. [90] by determining the 
EGFR mutational status in NSCLC and can represent a substitute for tissue biopsies 
when these are not available. Moreover, in 2016, the detection of EGFR gene muta-
tions in cfDNA using the cobas EGFR Mutation Test v2 achieved FDA approval as 
a companion diagnostic for erlotinib, becoming the first blood-based biopsy test 
approved for implementation in clinical decisions [91].
However, despite the evidence of potential clinical utility and even if it has 
been recommended (e.g., by the FDA) that the blood could be analyzed first to 
reduce the number of invasive biopsies in cancer patients, the lower sensitivity of 
ctDNA analyses prevents its use in clinical management for the moment, and the 
Table 2. 
(A) Number of observational and interventional clinical trials (clinical.gov) involving liquid biopsy in the 
main cancer types and (B) the applications of each circulating biomarkers (CTCs, circulating DNA, exosomes, 
microRNA, and TEPs).
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primary tumor analysis still remains the gold standard in NSCLC diagnostics of 
EGFR mutations.
5.2 MicroRNAs
MicroRNAs (miRNAs, miR-x), consisting in approximately 22 nucleotides, 
represent another potential blood biomarker in oncology. These noncoding small 
RNAs are master regulators of genic expression and consequently of many cellular 
processes. Alterations in the expression of microRNA genes have been shown to 
play in important role in human malignancies. These alterations can be caused by a 
variety of mechanisms, including deletions, amplifications, or mutations involving 
microRNA loci, by epigenetic silencing or by dysregulation of transcription factors 
targeting specific microRNAs [92]. The three major detection techniques for circu-
lating cell-free miRNA (cfmiRNA) analysis, following RNA extraction, comprise 
quantitative RT-PCR, microarray analyses, and deep sequencing. The assessment 
of cfmiRNA has been suggested for early diagnosis, prognosis, therapy monitoring, 
and therapeutic response prediction in different cancer types (e.g., lung, breast, 
colon, prostate, and ovary cancers and melanoma), as reviewed by Armand-Labit 
and Pradines [93].
5.3 Exosomes
Tumor and normal cells are known to release microvesicles such as exosomes 
(40–150 nm) into the circulation, discharging cellular content. Currently, one chal-
lenge for the analyses of circulating cell-free nucleic acids in blood is their instabil-
ity. Thus, due to their protective environment, the exosomes represent a valuable 
source for analysis of proteins, DNA, RNA, miRNA, lipids, and metabolites [94]. 
Ultracentrifugation, density-based separation, or immune-affinity capture using 
magnetic beads coated with anti-EpCAM antibodies can be used to isolate exosomes 
[95]. They are important regulators of the cellular niche, and their altered charac-
teristics in many diseases, such as cancer, suggest their importance for diagnostic 
and therapeutic applications and as drug delivery vehicles. Hoshino et al. demon-
strated that the composition of exosomal integrins could predict organ-specific 
metastasis and that tumor-derived exosomes participate in preparing the pre-
metastatic niche [96]. Correspondingly, the same group shows that a pro-metastatic 
phenotype of bone marrow progenitor cells is promoted by education through 
melanoma exosomes [97].
5.4 Tumor-educated platelets
A new emerging class of components for liquid biopsy is tumor-educated 
platelets (TEPs). These anucleated blood cells (second most abundant cell type in 
circulation) could be educated by tumor cells by the transfer of tumor-associated 
biomolecules, mostly RNA. Platelets are isolated by centrifugation and RNA can 
be subjected to RT-PCR [45]. Performing mRNA sequencing on TEPs, Best and his 
colleagues showed that cancer patients with different tumor types could be dis-
criminated from healthy individuals with 96% accuracy and that the primary tumor 
was correctly located with a precision of 71% [98]. Studies have shown that platelet 
count and platelet size can already provide clinically relevant information about the 
presence of cancer [99]. High platelet count is associated with increased mortality 
in a variety of cancers.
Furthermore, biomarkers (MET or HER2 expression/KRAS, EGFR, and PIK3CA 
mutations) were identified in surrogate TEP mRNA profiles, which might be tested 
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in future studies as potential predictors for targeted therapies. Recently, Diem et al. 
showed that elevated pretreatment platelet-to-lymphocyte ratios correlate with a 
reduced response rate to nivolumab anti-PD-L1 immunotherapy in NSCLC [100], 
indicating that circulating platelets may enhance a pro-tumorigenic effect in the 
presence of an antitumor immune response.
6. Conclusion
CTC as liquid biopsy represents a promising approach for personalized treatment 
in oncology. Lots of efforts have been made to overcome technical challenges for 
enrichment, detection, and characterization of these tumor cells. Nevertheless, low 
number (or even absence) of CTCs can weaken the reliability of CTC-based assays 
in some patients with current detection techniques. This points the need for further 
technological advances and procedure standardization. To introduce CTC tests into 
clinical trials, an intense validation of the technical aspects of the applied assays 
is currently executed in Europe by the EU-funded CANCER-ID network (www.
cancer-id.eu) that will be continued by the European Liquid Biopsy Society (ELBS).
Additionally, an extensive work has been made to understand biological pro-
cesses of cancer dissemination and metastasis, underlying different aspects for 
CTCs survival in bloodstream. This knowledge could improve pharmaceutical 
drug researches and therapeutic strategies for better clinical management of cancer 
patients.
Beside CTC analysis several other circulating biomarkers are under investiga-
tions and demonstrate real valuable data. It is now well accepted that there is not a 
perfect unique biomarker and that combining different circulating biomarkers can 
bring a huge benefit for precision medicine for cancer patients.
In conclusion, liquid biopsy diagnostics might help to focus the current cancer 
screening modalities, which would reduce side and healthcare costs. However, 
despite promising first results and the enormous interest by diagnostic companies 
and the public press, disease monitoring and early detection of cancer face serious 
challenges of both sensitivity and specificity.
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